Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in oncology, 11.2021, art. 778858, S. 1-7
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2021
- Urheber
-
Höh, Robert Benedikt
Würnschimmel, Christoph
Flammia, Rocco Simone
Horlemann, Benedikt
Sorce, Gabriele
Chierigo, Francesco
Tian, Zhe
Saad, Fred
Graefen, Markus
Gallucci, Michele
Briganti, Alberto
Terrone, Carlo
Shariat, Shahrokh F.
Tilki, Derya
Kluth, Luis
Mandel, Philipp
Chun, Felix
Karakiewicz, Pierre I.
- DOI
-
10.3389/fonc.2021.778858
- URN
-
urn:nbn:de:hebis:30:3-620579
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Höh, Robert Benedikt
- Würnschimmel, Christoph
- Flammia, Rocco Simone
- Horlemann, Benedikt
- Sorce, Gabriele
- Chierigo, Francesco
- Tian, Zhe
- Saad, Fred
- Graefen, Markus
- Gallucci, Michele
- Briganti, Alberto
- Terrone, Carlo
- Shariat, Shahrokh F.
- Tilki, Derya
- Kluth, Luis
- Mandel, Philipp
- Chun, Felix
- Karakiewicz, Pierre I.
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2021
Ähnliche Objekte (12)
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Sulforaphane reduces prostate cancer cell growth and proliferation in vitro by modulating the Cdk-Cyclin axis and expression of the CD44 variants 4, 5, and 7
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Sulforaphane reduces prostate cancer cell growth and proliferation in vitro by modulating the Cdk-Cyclin axis and expression of the CD44 variants 4, 5, and 7
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Sulforaphane reduces prostate cancer cell growth and proliferation in vitro by modulating the Cdk-Cyclin axis and expression of the CD44 variants 4, 5, and 7
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement